Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells

Sanjay Singh Institute of Life Sciences, School of Science and Technology, Ahmedabad University, Ahmedabad, Gujarat, India Abstract: Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Singh S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Liposomes Doxorubicin Celecoxib Cancer Nanotechnology Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/0fddc80cf1e046f99472a75fe1b0011d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0fddc80cf1e046f99472a75fe1b0011d
record_format	dspace
spelling	oai:doaj.org-article:0fddc80cf1e046f99472a75fe1b0011d2021-12-02T03:08:51ZLiposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells1178-2013https://doaj.org/article/0fddc80cf1e046f99472a75fe1b0011d2018-03-01T00:00:00Zhttps://www.dovepress.com/liposome-encapsulation-of-doxorubicin-and-celecoxib-in-combination-inh-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Sanjay Singh Institute of Life Sciences, School of Science and Technology, Ahmedabad University, Ahmedabad, Gujarat, India Abstract: Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target inhibitors have shown promising results in circumventing the development of resistance and inducing apoptosis in cancer cells/tissues. In this study, we encapsulated doxorubicin and celecoxib in a single liposome at a ratio of 1:10. These dual drug-encapsulated liposomes showed excellent anticancer activity compared to individually encapsulated liposomes. The expression of key proteins such as AKT and COX-2 was suppressed, which suggests that doxorubicin and celecoxib synergistically inhibit multiple key signaling pathways. Keywords: drug delivery, nanoliposomes, nanomedicines, cancer nanotechnologySingh SDove Medical PressarticleLiposomesDoxorubicinCelecoxibCancer NanotechnologyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 11-13 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Liposomes Doxorubicin Celecoxib Cancer Nanotechnology Medicine (General) R5-920
spellingShingle	Liposomes Doxorubicin Celecoxib Cancer Nanotechnology Medicine (General) R5-920 Singh S Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
description	Sanjay Singh Institute of Life Sciences, School of Science and Technology, Ahmedabad University, Ahmedabad, Gujarat, India Abstract: Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target inhibitors have shown promising results in circumventing the development of resistance and inducing apoptosis in cancer cells/tissues. In this study, we encapsulated doxorubicin and celecoxib in a single liposome at a ratio of 1:10. These dual drug-encapsulated liposomes showed excellent anticancer activity compared to individually encapsulated liposomes. The expression of key proteins such as AKT and COX-2 was suppressed, which suggests that doxorubicin and celecoxib synergistically inhibit multiple key signaling pathways. Keywords: drug delivery, nanoliposomes, nanomedicines, cancer nanotechnology
format	article
author	Singh S
author_facet	Singh S
author_sort	Singh S
title	Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
title_short	Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
title_full	Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
title_fullStr	Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
title_full_unstemmed	Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
title_sort	liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/0fddc80cf1e046f99472a75fe1b0011d
work_keys_str_mv	AT singhs liposomeencapsulationofdoxorubicinandcelecoxibincombinationinhibitsprogressionofhumanskincancercells
_version_	1718401901114949632

Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells

Ejemplares similares